Teva sues Mylan for patent infringement over Copaxone
JERUSALEM Teva filed a complaint against a generic drug maker this week, asserting four patents for its multiple sclerosis drug are being infringed.
Teva filed a suit in the U.S. District Court for the Southern District of New York, asserting that Mylan is infringing on four patents related to Copaxone (glatiramer acetate injection). Teva also previously filed a separate lawsuit against Mylan in October 2009 for infringement of multiple patents, including all seven "Orange Book" patents, covering the chemical composition of Copaxone, pharmaceutical compositions containing it, methods of using it and processes for making it. Those patents expire in May 2014 and September 2015. No trial date is scheduled.
Earlier this month, Teva also was involved in a patent dispute over the drug with Sandoz and Momenta Pharmaceuticals, in which a district court blocked the generic versions.